Compare · KRYS vs LEGN
KRYS vs LEGN
Side-by-side comparison of Krystal Biotech Inc. (KRYS) and Legend Biotech Corporation (LEGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. KRYS focuses on Biotechnology: Biological Products (No Diagnostic Substances), while LEGN focuses on Biotechnology: Pharmaceutical Preparations.
- KRYS is the larger of the two at $9.77B, about 2.5x LEGN ($3.85B).
- LEGN has been more active in the news (17 items in the past 4 weeks vs 3 for KRYS).
- LEGN has more recent analyst coverage (25 ratings vs 19 for KRYS).
- Company
- Krystal Biotech Inc.
- Legend Biotech Corporation
- Price
- -
- -
- Market cap
- $9.77B
- $3.85B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 3
- 17
- Recent ratings
- 19
- 25
Krystal Biotech Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Legend Biotech Corporation
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Latest KRYS
- SEC Form 8-K filed by Krystal Biotech Inc.
- Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
- Goldman resumed coverage on Krystal Biotech with a new price target
- SEC Form 4 filed by Director Rossi Dino A
- SEC Form 4 filed by Director Sutherland Everett Rand
- SEC Form 4 filed by Director Mazzacco Catherine
- SEC Form 4 filed by Director Mason Christopher
- SEC Form 4 filed by Director Janney Daniel
- SEC Form 4 filed by Director Gangolli Julian S
- President, R&D Krishnan Suma sold $8,982,986 worth of shares (25,000 units at $359.32) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,302,145 units (SEC Form 4)
Latest LEGN
- SEC Form 6-K filed by Legend Biotech Corporation
- Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
- SEC Form 6-K filed by Legend Biotech Corporation
- SEC Form S-8 filed by Legend Biotech Corporation
- Director Sanders Corazon (Corsee) D. sold $258,920 worth of Ordinary Shares (27,370 units at $9.46), decreasing direct ownership by 34% to 52,731 units (SEC Form 4)
- Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
- SEC Form 144 filed by Legend Biotech Corporation
- Director Heyman Tomas J. was granted 20,986 units of Ordinary Shares, increasing direct ownership by 64% to 53,720 units (SEC Form 4)
- Director Casey Patrick John was granted 20,986 units of Ordinary Shares, increasing direct ownership by 43% to 69,590 units (SEC Form 4)
- Director Mao Li was granted 20,986 units of Ordinary Shares, increasing direct ownership by 47% to 65,316 units (SEC Form 4)